Osimertinib and Low-Dose Itraconazole Combination: Vigilance in Elderly Patients

Abstract

Get full access to this article

View all access options for this article.

References

European Medicines Agency. Assessment report. http://www.ema.europa.eu/docs/en_GB/document_library/EPAPublic_assessment_report/human/004124/WC500202024.pdf. Published December 17, 2015. Accessed October 1, 2018.

Vishwanathan

Dickinson

et al . The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. Br J Clin Pharmacol. 2018;84:1156-1169. doi:10.1111/bcp.13534

Reddy

Walker

Sharma

Ballard

Vishwanathan

Development, verification, and prediction of osimertinib drug-drug interactions using PBPK modeling approach to inform drug label. CPT Pharmacometrics Syst Pharmacol. 2018;7:321-330. doi:10.1002/psp4.12289

Reis

Labat

Allard

et al . Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients. J Pharm Biomed Anal. 2018;158:174-183. doi:10.1016/j.jpba.2018.05.052

Horn

Hansten

Chan

LN.

Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41:674-680. doi:10.1345/aph.1H423

Bigot

Boudou-Rouquette

Arrondeau

et al . Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old. Invest New Drugs. 2017;35:242-246. doi:10.1007/s10637-016-0400-5